BELBUCA Drug Patent Profile

Which patents cover Belbuca, and when can generic versions of Belbuca launch?

Belbuca is a drug marketed by Bdsi and is included in one NDA. There are three patents protecting this drug and three Paragraph IV challenges.

This drug has seventy-six patent family members in twenty-seven countries.

The generic ingredient in BELBUCA is buprenorphine hydrochloride. There are twenty-nine drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the buprenorphine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Belbuca

A generic version of BELBUCA was approved as buprenorphine hydrochloride by HOSPIRA on June 3^rd, 1996.

Summary for BELBUCA

International Patents:	76
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	25
Clinical Trials:	9
Patent Applications:	18
Drug Prices:	Drug price information for BELBUCA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BELBUCA
What excipients (inactive ingredients) are in BELBUCA?	BELBUCA excipients list
DailyMed Link:	BELBUCA at DailyMed

See drug prices for BELBUCA

Recent Clinical Trials for BELBUCA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Carolinas Pain Institute	Phase 4
BioDelivery Sciences International	Phase 4
Medical College of Wisconsin	Phase 2

See all BELBUCA clinical trials

Pharmacology for BELBUCA

Drug Class	Partial Opioid Agonist
Mechanism of Action	Partial Opioid Agonists

Paragraph IV (Patent) Challenges for BELBUCA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BELBUCA	Buccal Film	buprenorphine hydrochloride	75 mcg and 150 mcg	207932	1	2016-10-24
BELBUCA	Buccal Film	buprenorphine hydrochloride	300 mcg, 450 mcg, 600 mcg and 750 mcg	207932	1	2016-10-04
BELBUCA	Buccal Film	buprenorphine hydrochloride	900 mcg	207932	1	2016-09-12

US Patents and Regulatory Information for BELBUCA

BELBUCA is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-001	Oct 23, 2015		RX	Yes	No	9,655,843		Y
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-006	Oct 23, 2015		RX	Yes	No	9,655,843		Y
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-003	Oct 23, 2015		RX	Yes	No	9,901,539
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-002	Oct 23, 2015		RX	Yes	No	9,901,539

Expired US Patents for BELBUCA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-005	Oct 23, 2015	6,159,498
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-002	Oct 23, 2015	6,159,498
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-006	Oct 23, 2015	7,579,019
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-005	Oct 23, 2015	7,579,019

International Patents for BELBUCA

See the table below for patents covering BELBUCA around the world.

Country	Patent Number	Title	Estimated Expiration
Croatia	P20160405
New Zealand	724912	Transmucosal drug delivery devices for use in chronic pain relief
Russian Federation	2009106177	СПОСОБ ТРАНСМУКОЗАЛЬНОЙ ДОСТАВКИ ЛЕКАРСТВ, СРЕДСТВО ДЛЯ ЕГО ОСУЩЕСТВЛЕНИЯ (ВАРИАНТЫ) И СПОСОБ ЛЕЧЕНИЯ БОЛИ
Israel	285091	התקנים לשחרור תרופות דרך ריריות לשימוש בהקלה על כאב כרוני (Transmucosal drug delivery devices for use in chronic pain relief)

BELBUCA (buprenorphine buccal film): Market dynamics and financial trajectory

Last updated: April 25, 2026

What is BELBUCA and how is it positioned in the opioid use landscape?

BELBUCA is a buprenorphine buccal film used for chronic pain management in patients who require around-the-clock, long-term opioid treatment. It is part of the broader opioid analgesic market segment and competes primarily on dosing convenience (buccal film), opioid-related safety positioning (partial agonist profile), and payer access for patients with long-term pain.

From a market-access standpoint, BELBUCA’s commercial outcomes are shaped by:

• Formulary inclusion and utilization management for chronic pain opioids (step edits, prior authorization, quantity limits).
• Class-level risk controls applied to opioid analgesics and buprenorphine products.
• Channel dynamics for long-term maintenance prescriptions versus acute-care opioids.

Key commercialization facts (as stated by the label):

• Indication: management of chronic pain severe enough to require continuous, long-term opioid treatment that cannot be managed by alternative treatments.
• Risk statements: strong emphasis on respiratory depression, misuse, abuse, addiction, and neonatal risk (women who use opioids).
• Product format: buccal film (designed for buccal administration).

Source: BELBUCA FDA label (accessed via DailyMed). [1]

How does the opioid analgesic market structure influence BELBUCA demand?

Demand for chronic opioid therapy is driven by a set of market forces that apply across the class, but with meaningful knock-on effects for specific buprenorphine products:

1) Payer restrictions and utilization management

Chronic pain opioid coverage typically relies on:

• Prior authorization triggered by diagnosis, previous therapy failures, or dose thresholds.
• Quantity limits and early refill rules.
• Step therapy for non-opioid or non-buprenorphine opioid alternatives.

These policies directly affect net sales conversion from prescriptions to reimbursed units, especially where multiple therapeutics compete on clinical similarity.

2) Shifts in prescribing behavior

Prescribers adjust selection based on:

• Safety perceptions and enforcement intensity around opioids.
• Clinical guidance and insurer criteria that prioritize lower abuse potential options.

Buprenorphine’s positioning as a partial agonist can reduce some prescriber hesitancy compared with full agonist opioids, but it does not eliminate access hurdles.

3) Competitive substitution within buprenorphine and adjacent analgesics

BELBUCA competes with:

• Other long-term opioid analgesics for chronic pain.
• Buprenorphine formulations in pain and other indications.
• Non-opioid alternatives where payers push formulary substitution.

Because substitution happens at the payer and prescriber level, BELBUCA’s revenue trajectory tends to track:

• formulary wins and losses,
• label-driven suitability for patient subgroups,
• and competitive pricing after discounts.

What financial trajectory indicators map to BELBUCA’s commercial performance?

A full financial trajectory requires company-level segment reporting, cohort-level prescriptions, and unit/net price trends. Those data are not included in the provided input, so the analysis below uses label-linked product status and market-structure determinants that typically determine BELBUCA’s revenue path.

Revenue drivers

• Net price and rebate structure: chronic pain opioids face aggressive contracting and payer discounting; even stable gross demand can translate into fluctuating net sales if rebate pressure rises.
• Script volume stability: BELBUCA’s value proposition is maintenance use; demand typically shows inertia, then step-change when payer status or competing products change.
• Utilization management: prior authorization stringency changes can cause abrupt drops in patient coverage even if brand awareness remains stable.

Revenue headwinds

• Class-level risk controls: regulatory scrutiny and payer tightening can reduce total reimbursed opioid volume.
• Competition: substitution toward alternative buprenorphine options or other chronic pain agents can cap growth.
• Generic/therapeutic substitution pressure (where applicable): once comparable products enter and payer pathways open, brand pricing leverage usually erodes.

How do patent and exclusivity dynamics typically affect BELBUCA’s pricing power?

BELBUCA’s forward market path depends on:

• the timing of regulatory exclusivities and
• the scope of patent protection covering formulation, manufacturing, and dosing regimen.

When exclusivity erodes or competitor entries increase, branded revenue typically shifts from growth to defense:

• price pressure rises,
• payer coverage becomes more conditional,
• and promotional efficiency declines.

This creates a pattern where net sales flatten first, then decline in the presence of substitutable competition.

What role do safety communications and risk mitigation play in commercial outcomes?

BELBUCA’s label includes prominent opioid risk warnings and risk mitigation elements, which affects both:

• prescriber confidence and
• payer willingness to cover.

The FDA label emphasizes:

• risk of respiratory depression, particularly during initiation or dose changes,
• risk of misuse, abuse, and addiction,
• risk of neonatal opioid withdrawal syndrome in women who use opioids during pregnancy,
• and strict patient counseling requirements.
  Source: BELBUCA FDA label (DailyMed). [1]

In commercial terms, heightened risk perception tends to:

• increase coverage friction through prior authorization,
• widen the gap between eligible patients and covered patients,
• and slow uptake in new prescriber cohorts.

How do competitors and therapy alternatives reshape BELBUCA’s market share?

Without live prescription and net sales data in the provided material, the share dynamics can only be stated structurally:

BELBUCA market share is mainly contested on:

• formulary placement (preferred versus non-preferred),
• authorization rules (criteria for initiation and continuation),
• dose flexibility and patient tolerance (clinical fit drives persistence),
• and contract pricing (rebate and discount competitiveness).

Substitution risk is highest when payers broaden coverage to additional opioid analgesics or other buprenorphine products for chronic pain.

What is the most decision-relevant implication for near- to mid-term financial performance?

BELBUCA’s financial trajectory in the near to mid term typically follows a contract-and-coverage model:

1. Coverage wins (new formulary listings or eased PA criteria) lift reimbursed scripts and net sales.
2. Coverage losses (tighter PA, step edits, or tighter quantity limits) reduce net sales faster than they reduce brand awareness.
3. Competitive entries usually cap upside by shifting payer selection to lower-cost or preferred alternatives.

Given BELBUCA’s chronic maintenance use profile and strong risk warnings in the label, payer friction is likely to remain a central variable in quarterly revenue variability, even when broader opioid prescribing volume stabilizes.

Financial outlook framework: what to watch in BELBUCA’s future revenue line

The following indicators are the most direct proxies for BELBUCA’s financial trajectory, based on how opioid brands are managed in US reimbursement:

Variable	What changes it	Expected impact on BELBUCA net sales
Payer formulary status	New plan contracting, therapeutic interchange policies	Upward step after inclusion; downside step after exclusion
Prior authorization thresholds	Criteria tightening (diagnosis, prior therapy, dose caps)	Volume reduction even if prescriber demand remains
Rebate pressure	Competitive bidding and broader opioid contracting	Net price compression, even if scripts hold
Competitive mix	Launches of substitutable therapies or preferred buprenorphine options	Market share dilution via switching
Persistence and dose stability	Tolerability and patient retention in chronic use	Sustains baseline scripts, moderates declines

Key takeaways

• BELBUCA’s revenue trajectory is structurally driven by chronic pain opioid market access: formulary placement, prior authorization rules, and rebate-driven net pricing.
• The FDA label’s emphasis on respiratory depression, misuse, and neonatal risks increases coverage friction and shapes prescriber and payer behavior. [1]
• The most decision-relevant near- to mid-term financial outcomes follow a coverage-and-contracting cycle, with revenue improving after eased access and declining faster after PA restrictions or competitive substitution.

FAQs

1) Is BELBUCA primarily a chronic pain product or an opioid use disorder product?

BELBUCA is for chronic pain management requiring continuous, long-term opioid therapy; it is not indicated for opioid use disorder in the cited label. [1]

2) What in the BELBUCA label most affects payer access?

The label’s major warnings and risk mitigation requirements tied to respiratory depression and misuse/abuse/addiction increase clinical and administrative scrutiny, which can translate into prior authorization barriers. [1]

3) What is the biggest market dynamic shaping BELBUCA demand?

Reimbursement controls in chronic pain opioids, especially formulary status and prior authorization thresholds, typically determine how much of eligible demand becomes reimbursed volume. [1]

4) Does the buccal film format materially change BELBUCA competitive positioning?

It can improve convenience and dosing practicality relative to other formulations, but net sales still depend mainly on payer access, contract pricing, and substitution dynamics. [1]

5) How does competition typically affect BELBUCA’s financial trajectory?

When payers broaden coverage or shift preference to lower-cost or preferred alternatives, BELBUCA commonly faces net price compression and share dilution, driving flattening and then decline if coverage worsens.

---

References

[1] U.S. National Library of Medicine. (n.d.). BELBUCA (buprenorphine) buccal film prescribing information (DailyMed). https://dailymed.nlm.nih.gov